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Apoptosis appears to be the death mechanism of pericyte loss observed in diabetic retinopathy. We have previously shown that advanced
glycation end-products (AGE-MGX) induce apoptosis of retinal pericytes in culture associated with diacylglycerol (DAG)/ceramide
production. In the present study, we investigated possible caspase involvement in this process. Bovine retinal pericytes (BRP) were cultured
with AGE-MGX and apoptosis examined after annexin V staining. Effects of peptidic inhibitors of caspases were determined on DAG/
ceramide production and apoptosis. Pan-caspase inhibitor z-VAD-fmk (50 AM) was able to inhibit both DAG/ceramide production and
apoptosis, whereas caspase-3-like inhibitor z-DEVD-fmk (50 AM) or caspase-9 inhibitor z-LEHD-fmk (50 AM) was only active on apoptosis.
This differential effect strongly suggests involvement of initiator caspase(s) upstream and effector caspase(s) downstream DAG/ceramide
production in AGE-mediated apoptosis. Pericyte treatment with caspase-8 inhibitor z-IETD-fmk (50 AM) did not protect cells against AGE-
induced apoptosis and we failed to detect caspase-8 in pericytes by immunoblotting assay. Interestingly, one inhibitor of caspase-10 and
related caspases z-AEVD-fmk (50 AM) inhibited both AGE-MGX-induced apoptosis and DAG/ceramide formation in pericytes. Cleavage of
caspase-10 precursor into its active subunits was demonstrated by immunoblotting assay in pericytes incubated with AGE-MGX. These
results strongly suggest that caspase-10, but not caspase-8, might be involved in the early phase of AGE-induced pericyte apoptosis, in
contrast to caspase-9 and -3-like enzymes involved after DAG/ceramide production. This finding may provide new therapeutic perspectives
for early treatment in diabetic retinopathy.
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E-mail address: marc.lecomte@merck.fr (M. Lecomte).This cellular alteration precedes other pathologic vascular
lesions such as microaneurysms, acellular capillaries forma-
tion [2], microthrombi, endothelial proliferation and angio-
genesis, which ultimately lead to blindness [3]. Apoptosis
seems to be the mechanism of death leading to early pericyte
loss observed in the course of retinopathy. Supporting this,
pericytes stained for markers of apoptosis have been detected
in situ in microvessels from retina of diabetic patients
recovered post-mortem [2,4,5]. One recent study also
showed that anti-pericyte autoantibodies are present in type
2 diabetic patients and are associated with early stage
retinopathy, suggesting new antigen expression by ‘‘activat-
ed’’ pericytes [6]. Despite this, mechanisms underlying
retinal pericyte apoptosis during diabetes are still not com-
pletely understood.
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mation of advanced glycation end-products (AGE) ob-
served during diabetes and their cytotoxic effects on
retinal pericyte. AGE are formed after a cascade of reac-
tions starting with a nonenzymatic reaction between ketones
or aldehydes and free amino groups located on proteins for
the most part, but also on nucleic acids or phospholipids.
During the course of diabetes, AGE accumulate mainly on
long-lived proteins and originate not only from the reaction
with glucose but also from other reactive dicarbonyls
derived from glucose, such as methylglyoxal [7], which is
increased in plasma of diabetic patients [8]. Retinal peri-
cytes are embedded in the basement membrane of micro-
vessels, composed of structural long-lived proteins shown
to form and accumulate Amadori products [9] leading to
AGE [10] in diabetic patients. Also, RAGE [11,12] and
other AGE receptors like p60 and p90 [13,14] have been
reported to be present in pericyte plasma membrane. The
possible effect of AGE on pericyte loss has been established
by studies using different glycation inhibitors, such as
aminoguanidine or pyridoxamine. Treatment of diabetic rats
with pyridoxamine during 29 weeks protected against
pericyte loss measured by acellular capillaries formation
and prevented formation of AGE (N(q)-(carboxymethyl)ly-
sine) in retinal microvessels [15]. Also, diabetic rats treated
for 26 weeks with aminoguanidine showed reduced AGE
accumulation in retinal microvessels and slower signs of
diabetic retinopathy progression measured as pericyte loss,
microaneurysms or acellular capillary formation [16]. An-
other line of evidence for toxic effect of AGE on pericytes
came from experiments where infusion of preformed AGE
into nondiabetic rats showed 25% reduction of pericyte
number after 2-week treatment [17] together with AGE
accumulation within or around pericytes [13]. Recent in
vitro studies by us [18] and others [19] have shown
cytotoxic effects of AGE on retinal pericytes leading to
apoptosis together with VEGF production in the later study.
Interestingly also, angiogenesis induced by AGE leads to
new vessels which are devoid of pericytes, suggesting that
AGE impair recruitment or differentiation of mural cell
precursors into pericytes [20].
Caspases are a family of cysteine proteases which cleave
subtrates at aspartic residues and which are crucial in the
initiation and the execution of the apoptotic program [21].
These proteases are present within the cell as inactive
precursors which require internal processing to become
active. Sequential cleavages at conserved Asp residues in
the caspase precursor form lead to liberation of large and
small subunits which rearrange to form a double (large +
small) dimer active form [22]. Initiator caspase-2, -8 and
-10 are at the apex of the signaling cascade induced by
apoptotic stimuli such as Fas or TNFa [23,24] and
caspase-9 is activated in response to agents leading to
cytochrome c release from the mitochondria [25]. Initiator
caspases activate either directly or indirectly effector
caspases including caspase-3, -6 or -7 [26,27], whichare the executioners of the apoptotic program leading to
cellular disintegration.
Our own study [18] showed that AGE-induced apoptosis
of pericytes has been associated with an intracellular for-
mation of diacylglycerol (DAG) and ceramide, produced
after activation of phosphatidylcholine-phospholipase C
(PC-PLC) and acidic sphingomyelinase (A-SMase), respec-
tively. Growing evidence indicates that ceramide production
during apoptosis can be under the control of initiator
caspase activation [28–30]. Ceramides produced during
apoptosis can further activate a variety of signaling path-
ways [31,32] leading to effector caspase activation after
mitochondrial damage [28,33]. In the present study, we
examined the relation between DAG/ceramide generation
and caspase activation in apoptotic pericytes and we focused
particularly on the nature of the initiator caspase involved in
the AGE-induced signaling pathway leading to retinal
pericyte apoptosis.2. Materials and methods
2.1. Materials
All products used for pericyte culture were from Sigma
(L’Isle d’Abeau, France) with the exception of fetal calf
serum (Invitrogen, Cergy-Pontoise, France) and collage-
nase/dispase (Roche, Meylan, France). The caspase inhib-
itor peptides, z-AEVD-fmk, z-DEVD-fmk, z-IETD-fmk,
z-LEHD-fmk and z-VAD-fmk, were obtained from Calbio-
chem (Nottingham, UK). DAG kinase, ceramides and DAG
(1-palmitoyl-3-stearoyl-rac-glycerol) were obtained from
Biomol (Le Perray-en-Yvelines, France). [g32P]adenosine-
5Vtrisphosphate (6 Ci/Amol) was obtained from Perkin
Elmer-NEN (Paris, France). Precoated TLC plates (silica
gel 60 without fluorescent indicator) were from Merck
(Fontenay-sous-Bois, France). The Annexin-V-FLUOS
staining kit was purchased from Roche. Nitrocellulose
membranes (BA 85, 0.45-Am porosity) used for protein
determinations were obtained from Whatman (Maidstone,
England). Sterile filtration was performed with acrodisc
filter (low protein binding, 0.2 Am) from Gelman Labora-
tory (Ann Arbor, MI, USA). PD-10 gel filtration columns
(G-25 M Sephadex) were from Amersham Pharmacia
Biotech (Orsay, France). SDS-polyacrylamide minigels
(ready gel Tris–HCl 12%), nitrocellulose membranes
(0.45 AM) and protein precision standards (broad range)
were from Bio-Rad (Marnes-La-Coquette, France). Nitro-
cellulose membrane blocking agent was either bovine
serum albumin (BSA) (Fraction V, 96% minimum) from
Sigma or non-fat dry milk (Re´gilait, Saint-Martin-Belle-
Roche, France) from a local general store. Rabbit poly-
clonal antibody against human caspase-10 (large subunit,
sc-7955) and goat polyclonal antibody against human
caspase-8 (large subunit, sc-6134), blocking peptide of
caspase-8 antibody, active recombinant caspases used as
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rabbit (sc-2313) and anti-goat (sc-2020) were purchased
from Biomol.
2.2. AGE-MGX preparation
AGE-MGX were prepared after incubation of 7.2 mg/ml
BSA (Fraction V, low endotoxin, fatty acid free) with 100
mM methylglyoxal in 100 mM phosphate buffer, pH 7.4, for
50 h at 37 jC in sterile conditions. Control preparation of
BSA was prepared as above but without methylglyoxal.
After incubation, AGE-MGX (or control-BSA) preparations
were eluted on PD-10 columns with Dulbecco’s modified
Eagle’s medium (DMEM) to remove salts and excess
methylglyoxal, further sterilized by filtration and kept at
 20 jC until used [18]. AGE-MGX (or control-BSA)
concentration was expressed as the BSA protein concentra-
tion added in the culture medium.
2.3. Culture of bovine retinal pericytes (BRP) and
incubation with peptidic caspase inhibitors
BRP were cultured from bovine retinal microvessels as
previously described [34]. Purity of BRP is almost 100%
pure as assessed after staining for a1-smooth muscle actin
and a pericyte specific glycolipid antigen (3G5) [35] and
confirmed after negative staining for von Willebrand’s
factor (Factor VIII-related antigen) [34] expressed in endo-
thelial cells. Briefly, microvessel fragments were isolated
from fresh bovine retinas (2 retinas/60-mm culture dish)
after Dounce homogenization and collagenase-dispase di-
gestion. Digested microvessel fragments were collected on
a sieve (70-Am mesh) before seeding on a fibronectin-
coated (4 Ag/cm2) culture dish. BRP in primary culture
were grown in 3-ml DMEM supplemented with 5 mM
glucose, 10% fetal calf serum, glutamine (2 mM), penicillin
(100 U/ml) and streptomycin (100 Ag/ml). Cells were
maintained in a 5% CO2 humidified atmosphere at 37 jC
and culture medium changed every 2 days. When confluent,
BRP were trypsinized (trypsin 0.5%, EDTA 0.2%), replated
on fibronectin-coated dishes (1:3, P1) and grown in the
same medium supplemented with 10 AM unesterified doco-
sahexaenoic acid (DHA) in order to restore the DHA
proportion of BRP total lipids close to the original value
observed in intact retinal microvessels [34]. AGE-MGX or
control-BSA (3 AM final concentration) with or without
caspase inhibitor peptides (stock solutions prepared in
dimethylsulfoxide, not exceeding 0.2% (v/v) final concen-
tration) were added directly to the supplemented culture
medium and cells were incubated chronically with these
various agents. P1 cells were split (1:3, P2) and cultured in
the same conditions as before for a total of 15 days
(P1 + P2) on average. For each independent experiment,
effects of AGE-MGX (or BSA-control) with or without
inhibitor peptides were analyzed on a same batch of cells
coming from the same primary culture.2.4. Apoptosis detection in cultured pericytes by FITC-
labeled annexin V staining
FITC-labeled annexin V binds to phosphatidylserine
exposed to the outer leaflet of membrane during apoptosis
and necrosis. Propidium iodide is used to differentiate
between apoptotic and necrotic cells. This DNA intercalating
agent is able to enter the nucleus during necrosis, staining
nucleus of necrotic cells in red. Analysis of phosphatidylser-
ine exposure to the outer leaflet of apoptotic pericyte mem-
branes was performed using an Annexin-V-FLUOS staining
kit, as previously described [18]. Every step described in the
procedure was done at 37 jC. After culture (P1 + P2) for an
average of 15 days with AGE-MGX (or control-BSA) with
or without peptidic caspase inhibitors, pericytes (35-mm
culture dish) were washed with PBS and incubated for 10
min with annexin V-FITC (10 Al) and propidium iodide (10
Al). Pericytes were further observed under an Axioplan
fluorescence microscope (Carl Zeiss with filter no. 9, 450
nm< k excitation < 500 nm and 515 nm< k detection < 565
nm). Necrotic and apoptotic cells were counted on 10
microscopic fields ( 200), representing a total cell count
comprised from 300 to 800 cells. Both categories of cells
were expressed as percentage of the total cell count.
2.5. Ceramide and DAG determinations
Total ceramides and DAG were quantified as previously
described [18] according to method of Preiss et al. [36] with
modifications. At the end of culture (P1 + P2, 15 days on
average) with AGE-MGX (or control-BSA) with or without
peptidic caspase inhibitors, pericytes (2 106 cells) were
washed three times with PBS (4 jC) and scraped on ice with
a rubber policeman in 2-ml water. Total cellular lipids were
then extracted by the method of Bligh and Dyer [37] and
dried under nitrogen. Briefly, ceramides and DAG in the
sample were metabolized to ceramides 1-[32P]phosphate
and 1-[32P]phosphatidates by DAG kinase (E. coli) with
[g32P]adenosine-5Vtrisphosphate for 1 h. Known amounts
of ceramide and DAG standards were treated in parallel.
Labeled lipids were extracted and spotted on TLC plates
(silica gel 60) developed in chloroform/methanol/acetic acid
(65:15:5 v/v/v). Following autoradiography, TLC spots
comigrating with ceramide-1-phosphate and phosphatidic
acid standards were scraped. Silicagel was humidified with
0.4-ml water/methanol (50:50 v/v) and Pico-Fluor (10 ml)
(Perkin Elmer-Packard, Rungis, France). Radioactivity
contained in all samples was quantified by liquid scintilla-
tion counting. Results were corrected for the protein content
of each sample. Proteins were determined by the method of
Schaffner and Weissmann [38].
DAG standard used in this study is made of saturated
fatty acids (16:0, 18:0) to increase stability during storage.
DAG-kinase from E. coli has a poor enzymatic activity for
these saturated molecular species of DAG, leading to one
overestimation of DAG amounts measured in whole lipids
ysica Acta 1689 (2004) 202–211
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results were expressed as percentage of control-BSA to
represent relative increase of intracellular levels of DAG
induced by AGE-MGX in pericytes.
2.6. Immunoblotting of caspases
After culture with AGE-MGX (or control-BSA) for a
total of 15 days on average, pericytes (2 106 cells) were
washed with PBS (4 jC) and scraped on ice with a rubber
policeman in 0.5 ml of 0.1 M Tris–HCl pH 8.0 containing
protease inhibitors (4.4 AM pepstatin, 6 AM leupeptin and
0.6 mM PMSF) and 10 mM EDTA. After centrifugation,
cell pellet was lysed in 100 Al of electrophoresis sample
loading buffer (0.15 M Tris–HCl pH 6.8, 5% SDS, 12.5%
glycerol, 12.5% h-mercaptoethanol, 1% bromophenol blue)
and boiled in one water heating bath for 3 min. Protein
amount for each sample was determined by the method of
Schaffner and Weissmann [38]. Aliquots (20 Ag total
proteins) from each sample, human recombinant caspase-
8 (1 Ag) as standard and molecular weight standards were
analysed by SDS-PAGE on a 12% SDS-polyacrylamide gel
and a 4% stacking gel with the discontinuous buffer system
of Laemmli [39]. Electrophoresis was performed on mini-
gels (mini-protean II cell, Bio-Rad) at 200 V in electropho-
resis buffer (25 mM Tris, 192 mM glycine, pH 8.3, SDS
0.1%), until bromophenol blue reached the bottom of the
gel. Proteins were electrophoretically transferred (mini-
transblot cell, Bio-Rad) to nitrocellulose membranes (45
min, 100V, 4 jC) in blotting buffer (25 mM Tris, 192 mM
glycine, pH 8.3, 20% methanol). After blotting, membranes
were stained with Ponceau red to check for protein transfer
of samples and further destained (2 times) in Tris buffered
saline (TBS) (10 mM Tris–HCl, pH 8.0, 150 mM NaCl).
Nitrocellulose membranes were saturated with non-antigen-
ic proteins, after overnight incubation (4 jC) with either
10% (w/v) powdered nonfat milk in TBS with 0.05% Tween
20 (TTBS) for western blots using rabbit polyclonal cas-
pase-10 antibody or with both 5% (w/v) BSA and 5% (w/v)
powdered nonfat milk in TTBS for Western blots using goat
polyclonal caspase-8 antibody.
After extensive washing with TTBS (15, 5, 5 min),
membranes were incubated for 2 h with primary antibodies
(raised against the large subunits of caspase-8 or -10) diluted
in TTBS (1/2000 for rabbit caspase-10 antibody and 1/1000
for goat caspase-8 antibody). Membranes were washed with
TTBS as above, incubated for 90 min with horseradish
peroxidase-coupled secondary antibodies diluted in TTBS
(1/6000 for anti-rabbit antibody and 1/3000 for anti-goat
antibody), washed again with TTBS and once in TBS (5
min), before detection of antigen by enhanced chemilumi-
nescence (ECL) assay. For caspase-8, in order to check
specificity of antibody recognition, caspase-8 antibody was
preincubated with blocking peptide in excess (1:5, w/w) in a
small PBS volume (1/2 dilution) overnight (4 jC) and used
in conditions described above for caspase-8 antibody.Blocking peptide for caspase-10 antibody was not available.
Caspase-10 western blots were analyzed after densitometry
scanning (GS-700 densitometer and Molecular Analyst
software from Bio-Rad).
2.7. Statistical analysis
Data are expressed as meansF S.D. of n independent
experiments. For each independent experiment, cells from
the same primary culture (P0) were cultured (P1 + P2) either
in control conditions (BSA-control with or without caspase
inhibitors) or in the presence of AGE-MGX (with or without
agents), allowing comparison of paired data.
The Wilcoxon signed-ranks test was used to define the
significance of the difference between (a) mean values of
each group (AGE-MGX/control-BSA) and (b) mean percent
inhibition observed with caspase inhibitors tested as com-
pared to the control group without inhibitors (0% inhibi-
tion). P < 0.05 was considered as statistically significant.3. Results
3.1. z-VAD-fmk, z-DEVD-fmk and z-LEHD-fmk have
differential effects on AGE-induced apoptosis and DAG/
ceramide production
Apoptosis of BRP induced by AGE-MGX (3 AM) was
assessed by annexin V-FITC labeling (Fig. 1A) and
expressed as the percentage of apoptotic cells in the total
cell population after culture during two passages (15 days
on average), as described previously [18]. Apoptosis rate
increased three times in pericytes cultured with AGE-MGX
(3 AM) as compared to cells cultured with control-BSA only
(7.40F 0.62% vs. 2.64F 0.60%, meanF S.D., n = 6,
P < 0.05) (Fig. 1B). Apoptosis induced by AGE-MGX was
dose-dependent [18] and evaluated also after oligonucleo-
some quantitation with same results as described above [18].
Percentage of necrotic cells in the cell population was
always below 0.1% and this percentage was not affected
by the type of treatment (not shown). In parallel to apopto-
sis, lipids (DAG and ceramides) (Fig. 1C) involved in the
apoptotic signaling pathway induced by AGE (135F 7%
and 145F 11% of control-BSA for DAG and ceramides
(P < 0.05), respectively) were also measured [18] in order to
investigate possible involvement of caspases on the produc-
tion of these lipid mediators.
One peptidic inhibitor of caspases, substituted at NH2
and COOH termini, z-VAD-fmk (a pan-caspase inhibitor)
[40,41], was first tested in order to determine whether
caspases could be involved in the apoptotic pathway acti-
vated by AGE-MGX in BRP. z-VAD-fmk inhibited com-
pletely BRP apoptosis induced by AGE-MGX (Fig. 1B)
which returned to the basal level observed with control-BSA
alone (P < 0.05 as compared to AGE-MGX without z-VAD-
fmk). In addition, z-VAD-fmk was able to completely block
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(Fig. 1C) (P < 0.05 as compared to AGE-MGX alone),
suggesting involvement of caspase(s) upstream of DAG/
ceramide production.
We further tested two substituted inhibitors z-DEVD-fmk
(a caspase-3-like (caspase-3, -6, -7, -8 and -10) inhibitor)
[40 41] and z-LEHD-fmk (a caspase-9 inhibitor) [42] to
investigate possible sequential activation of caspase-9 and
-3, -6 or -7 in this apoptotic cascade. Both z-DEVD-fmk andz-LEHD-fmk strongly inhibited (100% and 75%, respective-
ly, P < 0.05 as compared to AGE-MGX alone) pericyte
apoptosis induced by AGE-MGX (Fig. 2A) without inhibit-
ing DAG/ceramide production induced by AGE-MGX in
BRP (Fig. 2B and C, respectively).
3.2. Caspase-8 is not involved in BRP apoptosis induced by
AGE-MGX
We investigated the possible involvement of initiator
caspase-8 in the signaling pathway leading to BRP apopto-
sis induced by AGE-MGX. Incubation of cells (P1 + P2)
with AGE-MGX for 15 days on average in the presence of
z-IETD-fmk (50 AM), a caspase-8 inhibitor [40], did not
affect AGE-induced apoptosis (Fig. 3A). We further studied
caspase-8 zymogen expression in BRP and activation in
AGE-treated BRP after immunoblotting using one poly-
clonal antibody raised against the large subunit of human
caspase-8 (Fig. 4). Proteins from pericytes incubated with
AGE-MGX (or control-BSA) were separated after electro-
phoresis and caspase-8 was detected after Western blot with
caspase-8 antibody. The active form of human caspase-8 was
used as standard. Western blot was done with caspase-
8 antibody incubated (Fig. 4, lanes 5 to 7) or not (lanes 1
to 4) with one antibody blocking peptide. Caspase-8 anti-
body recognized only one major band of (Mr) 45000
approximately either before (Fig. 4, lanes 2 and 3) or after
(Fig. 4, lanes 6 and 7) incubation with the blocking peptide.
Blocking peptide was able to abolish specific antigenic
recognition of caspase-8, as shown in Fig. 4, where detec-
tion of intermediary fragment (p30), large (p18) and small
(p12) subunits of human caspase-8 is almost abolished after
incubation with the blocking peptide (compare lanes 5 and
4). These results obtained with one blocking peptide on
caspase-8 recognition support that protein band of (Mr)
45000 is nonspecific and suggest that caspase-8 is not
detected in bovine pericytes incubated with AGE-MGX or
control-BSA.Fig. 1. Effect of z-VAD-fmk (pan caspase inhibitor) on AGE-induced
pericyte apoptosis and cellular DAG/ceramide levels. Cells were cultured
throughout two passages (15 days on average) with AGE-MGX or control-
BSA (3 AM) with or without inhibitor peptide z-VAD-fmk (50 AM).
Apoptosis was detected (A) and quantified (B) by the annexin V-FITC
method, as described in Materials and methods. Panel A is a surperimposed
photomicrograph of pericytes cultured with AGE-MGX (day 15) which
represents the same field (original magnification  100) in phase-contrast
and in fluorescence (FITC), showing annexin V-positive cells in green.
Results are expressed as percentage of apoptotic cells (B) and are
meanF S.D. of six independent experiments. DAG and ceramides levels
in cells treated with z-VAD-fmk (C) were assayed by the DAG kinase
method, as described in Materials and methods. Results, expressed as
percentage of control-BSA, are meanF S.D. of five independent experi-
ments. Amount of ceramides measured in cells cultured with control-BSA
(100%) for experiments with z-VAD-fmk was 720F 140 ng ceramides/mg
proteins. DAG amounts are probably overestimated as discussed in
Materials and methods. *: P < 0.05 vs. control-BSA; y: P< 0.05 vs. AGE-
MGX without agents. (For color see online version).
Fig. 2. Effects of z-DEVD-fmk (caspase-3-like enzyme inhibitor) and z-
LEHD-fmk (caspase-9 inhibitor) on AGE-induced apoptosis and cellular
DAG/ceramide levels. Cells were cultured throughout two passages (15
days on average) with AGE-MGX or control-BSA (3 AM) with or without
caspase inhibitory peptide (50 AM). (A) Apoptosis was detected and
quantified by the annexin V-FITC method, as described in Materials and
methods. Results are expressed as percentage of apoptotic cells and are
meanF S.D. of six or five independent experiments for z-DEVD-fmk and
z-LEHD-fmk, respectively. DAG and ceramide levels in cells treated with
z-DEVD-fmk (B) or z-LEHD-fmk (C) were assayed by the DAG kinase
method, as described in Materials and methods. Results, expressed as
percentage of control-BSA, are meanF S.D. of three independent experi-
ments for both inhibitory peptides. Amount of ceramides measured in cells
cultured with control-BSA (100%) for experiments with z-DEVD-fmk was
725F 114 ng ceramides/mg proteins and 689F 99 ng ceramides/mg
proteins for experiments with z-LEHD-fmk. DAG amounts are probably
overestimated as discussed in Materials and methods. *: P < 0.05 vs.
control-BSA, y: P< 0.05 vs. AGE-MGX without agents.
 
Fig. 3. Effects of z-IETD-fmk (caspase-8 inhibitor) and z-AEVD-fmk
(caspase-10, -6, -8 and -9 inhibitor) on AGE-induced pericyte apoptosis and
DAG/ceramide levels. Cells were cultured throughout two passages (15
days on average) with AGE-MGX or control-BSA (3 AM) with or without
caspase inhibitory peptide (50 AM). (A) Apoptosis was detected and
quantified by the annexin V-FITC method, as described in Materials and
methods. Results are expressed as percentage of apoptotic cells and are
meanF S.D. of three or six independent experiments for z-IETD-fmk and
z-AEVD-fmk, respectively. (B) DAG and ceramides levels in cells treated
with z-AEVD-fmk were assayed by the DAG kinase method, as described
in Materials and methods. Results, expressed as percentage of control-BSA,
are meanF S.D. of six independent experiments. Amount of ceramides
measured in cells cultured with control-BSA (100%) for experiments with
z-AEVD-fmk was 712F 132 ng ceramides/mg proteins. DAG amounts are
probably overestimated as discussed in Materials and methods. *: P < 0.05
vs. control-BSA, y: P < 0.05 vs. AGE-MGX without agents.
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AGE-MGX
We further investigated the possible involvement of
initiator caspase-10 in the apoptotic pathway induced by
AGE-MGX in pericytes. The effect of z-AEVD-fmk, an
inhibitor of caspase-10 and related caspase-6, -8 and -9 [41],
was tested on apoptosis and DAG/ceramide production in
BRP cultured chronically (15 days) with AGE-MGX. z-
Fig. 5. AGE-induced activation of caspase-10 in BRP. Cells were cultured
throughout two passages (15 days on average) with AGE-MGX or control-
BSA (3 AM) (A) Molecular weight standards (1 Al) and total proteins from
cellular lysates (20 Ag) were analyzed by immunoblotting as described in
Materials and methods. Polyclonal caspase-10 antibody used was raised
against the large subunit of active caspase 10 and recognizes both the
precursor form and the active caspase. Relative molecular mass of detected
proteins was determined after comparison with proteins of known
molecular mass (MW). This caspase-10 immunoblot is representative of
seven independent experiments. (B) p64 and p27 bands detected in lanes 2
and 3 were quantified by densitometric scanning. Results, expressed as
percentage of BSA-control, are meanF S.D. of seven independent
experiments. *P < 0.05 vs. control-BSA.
Fig. 4. Caspase-8 is not detected in BRP treated with AGE-MGX or
control-BSA. Cells were cultured throughout two passages (15 days on
average) with AGE-MGX or control-BSA (3 AM). Molecular weight
standards (1 Al), total proteins from cellular lysates (20 Ag) or human
caspase-8 (1 Ag) were analyzed by immunoblotting as described in
Materials and methods. Samples were revealed with primary anti-caspase-
8 antibody preincubated (lanes 5, 6, 7) or not (lanes 2, 3, 4) with blocking
peptide as described in Materials and methods. Relative molecular mass of
detected proteins was determined after comparison with proteins of known
molecular mass (MW). This caspase-8 Western blot is representative of four
independent experiments coming from different primary cultures.
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apoptosis (Fig. 3A) and DAG/ceramide formation (Fig. 3B)
in pericytes incubated with AGE-MGX. This simultaneous
effect of z-AEVD-fmk on apoptosis and DAG/ceramide is
different from the one observed with a specific caspase-
8 inhibitor (no effect on apoptosis, see Fig. 3A) or with
either a specific caspase-9 or a caspase-3-like (including
caspase-6) inhibitor (no effect on DAG/ceramide produc-
tion, see Fig. 2C and B, respectively). We further looked at
possible caspase-10 expression and activation in BRP incu-
bated chronically (P1 + P2) with AGE-MGX for an average
duration of 15 days, after Western blotting of total proteins
from cellular homogenates (Fig. 5A). Caspase-10 antibody
used in these experiments is a polyclonal antibody raised
against the large human caspase-10 subunit allowing rec-
ognition of both precursor zymogen and activated caspase
(large subunit). Immunodetection with caspase-10 antibody
shows a major band of (Mr) 64000 (precursor) in control
cells (control-BSA) (Fig. 5A, lane 2) whose intensity is
decreased in AGE-MGX treated cells, together with a
parallel increase in intensity of a protein band of (Mr)
27000 (large subunit) (Fig. 5A, lane 3). From the whole
data set of blots analysed by densitometric scanning (Fig.
5B), we observed a significant decrease (40F 13%,
P < 0.05) of (Mr) 64000 band together with a significant
increase of (Mr) 27000 band (54F 30%, P < 0.05). Relative
molecular masses (Mr) as reported above were determined
after comparison of migration distances with known molec-
ular weight standards in seven independent experiments. In
control experiments using recombinant human caspase-10,we checked the specificity of our antibody against the large
subunit of caspase-10 (not shown).4. Discussion
We have previously shown that AGE-MGX are able to
induce pericyte apoptosis associated to sequential activation
of PC-PLC coupled to A-SMase, leading to intracellular
production of DAG and ceramides [18]. To our knowledge,
the results reported here are the first to document involve-
ment of initiator and effector caspases in apoptosis of retinal
pericytes induced by AGE. This work further identifies
caspase-10 as one initiator caspase acting in the early phase
of AGE-induced apoptosis of pericytes based on experi-
ments done with caspase peptidic inhibitors but also with
specific antibodies used in Western blots.
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z-VAD-fmk, show that this peptide was able to completely
inhibit AGE-induced apoptosis of pericytes but also DAG
and ceramide accumulation in these cells, pointing to
possible implication of caspases upstream of DAG and
ceramide generation in the signaling cascade induced by
AGE. Initiator caspases have been described in some
apoptotic models to control A-SMase activation, reported
to be dependent [28] or not [43,44] on PC-PLC activation.
A-SMase activation has also been shown to be dependent on
FADD [44], an adaptator molecule involved only in cas-
pase-8 and -10 death receptor recruitment and activation
[23,45], suggesting that these caspases might be involved in
A-SMase activation during AGE-induced apoptotic process
in retinal pericytes.
Looking at the exact nature of initiator caspase activated
upstream of DAG/ceramide generation in AGE-induced
apoptosis, we first investigated possible caspase-8 activation.
Caspase-8 inhibitor z-IETD-fmk did not protect pericytes
against AGE-induced apoptosis and we did not detect
caspase-8 in retinal pericytes in our western blot experi-
ments. These results strongly suggest that caspase-8 is not
involved in the AGE-induced signaling pathway leading to
pericyte death.
We further focused on caspase-10. z-AEVD-fmk, an
inhibitor of caspase-10 and related caspase-6, -8 and-9,
inhibited both AGE-induced apoptosis and DAG/ceramide
formation in pericytes. This result is different from the one
observed with a specific caspase-8 inhibitor which did not
inhibit apoptosis or with either a specific caspase-9 inhibitor
or a caspase-3-like (including caspase-6) inhibitor which did
not affect DAG/ceramide formation. Taken together, these
results strongly suggest that caspase-10 was involved up-
stream of DAG/ceramide formation in AGE-induced apopto-
sis of pericytes. Involvement of caspase-10 in AGE-induced
apoptosis was further strengthened after immunoblotting
experiments using an antibody raised against the large
subunit of caspase-10 human enzyme. Western blots of
proteins coming from pericytes incubated with AGE-
MGX show a protein of (Mr) 64000 approximately which
intensity is decreased as compared to control cells (BSA-
control), and a protein of (Mr) 27000 approximately which
is almost absent in control cells. This profile is in agreement
with the one observed for caspase activation, the decrease of
one caspase precursor band in parallel with increased
intensity of the large subunit band only due to our antibody
specificity. Relative molecular weights of bovine caspase-10
precursor (p64) and large subunit (p27) reported here are a
little bigger (about 4 kDa) than the ones reported for long
isoforms of human caspase-10/b (p59/p23) [46] and -10/d
(p59/p23) [47]. This could reflect species differences re-
garding protein sequences, as observed for example for the
bovine receptor RAGE for AGE which is bigger than its
human counterpart [48].
Caspase-10 is a receptor-proximal caspase involved in
death receptor-mediated apoptosis which has been de-scribed only recently. Proteolytic cleavage of pro-caspase-
10 into active caspase-10 requires ligand-induced oligomer-
isation of death receptor (Fas or TNF-R) and recruitment of
adaptator molecule FADD to the cytoplasmic death domain
of the receptor [45]. Caspase-10 activation in retinal peri-
cytes submitted to AGE-MGX suggests the involvement of
transmembrane receptor in AGE-induced apoptosis. Apo-
ptotic effects of AGE-MGX in retinal pericytes could be
mediated either directly by AGE-MGX interaction with
specific receptor(s) and induction of the apoptotic cascade,
or indirectly after synthesis of one apoptosis mediator
acting as one autocrine signal for pericyte apoptosis. Upon
activation, RAGE receptor for AGE has been shown to
induce secretion of TNFa in several cell lines like macro-
phages [49] or microvascular endothelial cells through NF-
nB activation [50]. Pericytes in hyperglycemia are also able
to secrete TNFa [51] through NF-nB. The other possibility
is that binding of AGE to the AGE-receptor complex (p60,
p90 and galectin 3) [52] found in cholesterol-rich lipid raft
could activate caspase-10 by a mechanism which remains
to be elucidated. One speculation could be that some
protein like CARMA1 [53], containing a caspase recruit-
ment motif and found constitutively associated with lipid
rafts, could segregate with AGE receptor complex and
activate caspase-10.
We have also examined the effects of z-LEHD-fmk, a
specific inhibitor for caspase-9 [42], and z-DEVD-fmk, a
specific inhibitor for caspase-3 and -7 and less active on
caspase-6, -8 and -10 [41], on AGE-induced apoptosis and
DAG/ceramide production. Interestingly, either z-LEHD-
fmk or z-DEVD-fmk was able to inhibit apoptosis of
pericytes induced by AGE-MGX, without affecting DAG
and ceramide production in these cells. Taken together,
these results suggest that caspase-9 and caspase-3, -6 or -7
act downstream of DAG and ceramide in the cascade
induced by AGE-MGX. Activation of caspase-9 requires
apoptosome formation dependent on mitochondrial leakage
of cytochrome c [25]. One recent study on mesangial cells
suggests a mechanism by which AGE can lead to mito-
chondrial alteration and caspase-9 activation: mesangial cell
apoptosis induced by AGE leads to Bax overexpression
[54], which in turn is able to induce mitochondrial cyto-
chrome c leakage [55]. Supporting this, Bax overexpression
in apoptotic pericytes has already been documented in
retinas obtained postmortem from diabetic patients [5].
Activation of effector caspase-3, -6 or -7 in pericyte apo-
ptosis, as suggested here, is supported by studies made by Li
et al. [4] where overexpression of caspase-3 gene has been
demonstrated in apoptotic pericytes purified from retinas
obtained from diabetic patients.
In addition to this, activation of a large panel (not
including caspase-10) of caspases in whole retinas of
diabetic patients or mice in the course of diabetic retinop-
athy has recently been demonstrated [56]. Time-course
analysis of caspase activation in retinal homogenates of
diabetic mice revealed that caspase-3 induction was associ-
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undergo apoptosis [56], in accordance with our in vitro data
on pericyte apoptosis induced by AGE. This study also
showed increase of caspase-3 and -6 activities in homoge-
nates of retinas obtained from diabetic type 2 patients.
In conclusion, our study shows involvement of caspases
in the apoptotic cascade induced by AGE-MGX in BRP.
AGE-induced apoptosis of pericytes seems to trigger one
caspase that initiates the apoptotic signaling cascade (initi-
ator caspase-10) but also caspases that execute the apoptotic
program such as caspase-3, -6 or -7 and caspase-9. Accel-
erated apoptosis of pericytes was recently found to precede
the characteristic diabetic vascular damages (microaneur-
ysms, acellular capillaries) characteristic of diabetic retinop-
athy [2] and may therefore be a key event in the early phase
development of this ocular complication of diabetes. Iden-
tification of caspases such as initiator caspase-10 involved
in AGE-induced apoptosis of retinal pericytes may provide
new therapeutic perspectives in early diabetic retinopathy.Acknowledgements
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